Vaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Phase 1 Part B End-of-Treatment Data Show UB-312 is Well Tolerated and Immunogenic in Parkinson’s Disease Patients VXX-401 Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in... | November 10, 2022
New York United States United Kingdom University Of Texas Ben Matone Therapeutics Goods Administration
Source: marketscreener.com